CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations

BackgroundAfatinib is a potent, irreversible second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non-small cell lung cancer (NSCLC) patients harboring either common or uncommon EGFR mutations. However, data on its activity a...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Liping Kang, Jianliang Mai, Weiting Liang, Qihua Zou, Caiwen Huang, Yongbin Lin, Ying Liang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Subjects:	NSCLC afatinib brain metastases CNS efficacy uncommon EGFR mutations
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1094195/full